Shuttle Pharmaceuticals Holdings, Inc. – NASDAQ:SHPH

Add to watchlist

$3.17

+2.42

+327.8%

Market closed

Open in about 2 hours

+74.64%

month

+74.64%

quarter

+52.41%

year

Market Cap	2.25M
Enterprise value	6.09M

P/E	-4.43
EV/Sales	N/A
EV/EBITDA	-1.59
Price/Sales	N/A
Price/Book	1.79
PEG ratio	0.01
EPS	-0.45

Revenue	N/A
EBITDA	-5.68M
Income	-7.34M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Profit margin
Jun 2023	0	-2.18M
Sep 2023	0	-1.79M
Dec 2023	9.65K	-1.64M	-16989.44%
Mar 2024	0	-1.73M

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Payout ratio
Payout ratio	0%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Dividend Yield
2018
2020
2021
2022	0.25%
2023

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Debt to assets
Jun 2023	8837101	1.90M	21.52%
Sep 2023	7375818	1.76M	23.94%
Dec 2023	5951736	1.89M	31.86%
Mar 2024	4753921	1.99M	41.91%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Cash Flow
Jun 2023	-1.64M	62.80K	-139.22K
Sep 2023	-1.53M	-25.85K	0
Dec 2023	-1.06M	87.03K	-334.44K
Mar 2024	-1.23M	101.29K	-40K

Shuttle Pharmaceuticals Holdings alternative data

Shuttle Pharmaceuticals Holdings
Employees

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Employee count
Aug 2023	7
Sep 2023	7
Oct 2023	7
Nov 2023	7
Dec 2023	7
Jan 2024	7
Feb 2024	7
Mar 2024	8
Apr 2024	8
May 2024	8
Jun 2024	8
Jul 2024	8

Shuttle Pharmaceuticals Holdings
Insider Trading

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	0	7078

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	13 Dec 2023	BROWN MILTON director director	Common Stock	2,921	$0.46	$1,352
Sale	13 Dec 2023	JACOBS BETTE director director	Common Stock	4,157	$0.46	$1,925
Sale	29 Dec 2022	RICHARDS STEVEN M director director	COMMON STOCK	995	$1.61	$1,597
Sale	29 Dec 2022	BROWN MILTON director director	COMMON STOCK	995	$1.61	$1,597
Sale	29 Dec 2022	ADKINS WILLIAM other: Former Director other: Former Director	COMMON STOCK	995	$1.61	$1,597
Sale	29 Dec 2022	DRITSCHILO ANATOLY director, 10 percent owner, officer: CE.. director, 10 percent owner, off..	COMMON STOCK	8,372	$1.61	$13,437
Sale	29 Dec 2022	JACOBS BETTE director director	CLASS A COMMON STOCK	4,366	$1.61	$7,007
Sale	29 Dec 2022	JUNG MIRA officer: Chief Scientific Officer officer: Chief Scientific Officer	CLASS A COMMON STOCK	328	$1.61	$526
Sale	29 Dec 2022	RICH TYVIN officer: Chief Medical Officer officer: Chief Medical Officer	COMMON STOCK	1,414	$1.61	$2,269
Sale	29 Dec 2022	DRITSCHILO PETER officer: President and COO officer: President and COO	COMMON STOCK	3,820	$1.61	$6,131

SHPH insider trading transactions

Shuttle Pharmaceuticals Holdings
Latest News

Tuesday, 26 November 2024
09:00	Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient	globenewswire.com
Wednesday, 13 November 2024
17:00	Shuttle Pharma Provides Third Quarter 2024 Corporate Update	globenewswire.com
Tuesday, 29 October 2024
21:05	Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules	globenewswire.com
Monday, 28 October 2024
16:05	Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma	globenewswire.com
Monday, 16 September 2024
09:00	Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma	globenewswire.com
Wednesday, 4 September 2024
16:15	Shuttle Pharma Provides Second Quarter 2024 Corporate Update	globenewswire.com
Monday, 26 August 2024
16:10	Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)	globenewswire.com
Wednesday, 14 August 2024
16:10	Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	globenewswire.com
Friday, 19 July 2024
09:00	Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE	globenewswire.com
Tuesday, 18 June 2024
09:00	Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer	globenewswire.com
Wednesday, 22 May 2024
16:15	Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	globenewswire.com
Tuesday, 14 May 2024
09:00	Shuttle Pharma Provides First Quarter 2024 Corporate Update	globenewswire.com
Tuesday, 23 April 2024
16:15	Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024	GlobeNewsWire
Wednesday, 3 April 2024
09:00	Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024	GlobeNewsWire
Wednesday, 24 May 2023
06:00	Trading Penny Stocks on a Budget, Maximizing Returns	PennyStocks
Friday, 13 January 2023
10:39	Penny Stocks To Buy? 4 Hot Stocks With Big News This Week	PennyStocks
Tuesday, 6 December 2022
06:00	Tips for Buying Penny Stocks Under $3 Right Now	PennyStocks
Monday, 17 October 2022
19:41	These Were The Five Best And Worst Performing Healthcare Stocks In September 2022	24/7 Wall Street
Friday, 16 September 2022
15:18	Shuttle Pharmaceuticals ($SHPH) Awarded New HDAC Inhibitor Patents for Cancer Treatment	Green Stock News
Friday, 9 September 2022
17:05	Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week	The Motley Fool

Frequently Asked Questions (FAQ)

What's the price of Shuttle Pharmaceuticals Holdings stock today?

One share of Shuttle Pharmaceuticals Holdings stock can currently be purchased for approximately $3.17.
When is Shuttle Pharmaceuticals Holdings's next earnings date?

Unfortunately, Shuttle Pharmaceuticals Holdings's (SHPH) next earnings date is currently unknown.
Does Shuttle Pharmaceuticals Holdings pay dividends?

No, Shuttle Pharmaceuticals Holdings does not pay dividends.
How much money does Shuttle Pharmaceuticals Holdings make?

Shuttle Pharmaceuticals Holdings has a market capitalization of 2.25M.
What is Shuttle Pharmaceuticals Holdings's stock symbol?

Shuttle Pharmaceuticals Holdings, Inc. is traded on the NASDAQ under the ticker symbol "SHPH".
What is Shuttle Pharmaceuticals Holdings's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Shuttle Pharmaceuticals Holdings?

Shares of Shuttle Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Shuttle Pharmaceuticals Holdings have?

As Jul 2024, Shuttle Pharmaceuticals Holdings employs 8 workers.
When Shuttle Pharmaceuticals Holdings went public?

Shuttle Pharmaceuticals Holdings, Inc. is publicly traded company for more then 3 years since IPO on 31 Aug 2022.
What is Shuttle Pharmaceuticals Holdings's official website?

The official website for Shuttle Pharmaceuticals Holdings is shuttlepharma.com.
Where are Shuttle Pharmaceuticals Holdings's headquarters?

Shuttle Pharmaceuticals Holdings is headquartered at One Research Court, Rockville, MD.
How can i contact Shuttle Pharmaceuticals Holdings?

Shuttle Pharmaceuticals Holdings's mailing address is One Research Court, Rockville, MD and company can be reached via phone at +240 4034212.

Shuttle Pharmaceuticals Holdings, Inc.

shuttlepharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

+240 4034212

One Research Court
Rockville, MD 20850

CIK: 0001757499
ISIN: US8256932034
CUSIP: 825693203